Mark Abi Nader, MD
Nephrology · Memphis, TNNPI 1841538147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 322 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.
Across 322 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$1K
- AstraZeneca$924
- Aurinia Pharma U.S., Inc.$662
- Otsuka America Pharmaceutical, Inc.$630
- Fresenius USA Marketing, Inc.$532
- Travere Therapeutics, Inc.$520
- plus $3K from 18 others
What the payments were for
- Food & beverage$6,79895%
- Education$3425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 70 | $1,072 |
| AstraZeneca(2 entities) | 34 | $924 |
| Aurinia Pharma U.S., Inc. | 28 | $662 |
| Otsuka America Pharmaceutical, Inc. | 27 | $630 |
| Fresenius USA Marketing, Inc. | 28 | $532 |
| Travere Therapeutics, Inc. | 30 | $520 |
| Vifor Pharma, Inc. | 22 | $422 |
| Ardelyx, Inc. | 10 | $365 |
| Novartis | 9 | $277 |
| Amgen | 12 | $260 |
| Medtronic | 2 | $250 |
| OPKO Pharmaceuticals, LLC | 13 | $233 |
| Mallinckrodt Hospital Products Inc. | 4 | $188 |
| Boehringer Ingelheim | 8 | $136 |
| Nxstage Medical, Inc. | 1 | $135 |
| GSK | 6 | $114 |
| Calliditas Therapeutics US Inc. | 6 | $113 |
| Veloxis Pharmaceuticals, Inc. | 1 | $96 |
| Akebia Therapeutics Inc | 3 | $61 |
| Recor Medical Inc | 3 | $51 |
| Lilly USA, LLC | 2 | $45 |
| Cormedix Inc. | 1 | $28 |
| Strongbridge US Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$316
- ELLIPSYS VASCULAR ACCESS SYSTEM$250
- LIBERTY SELECT CYCLER$135
- NXSTAGE SYSTEM ONE$135
- JYNARQUE$119
- TERLIVAZ$108
- XPHOZAH 30 MG$104
How this compares
$7,141 in reported general payments places this provider in the 80th percentile of 229 nephrology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 32 | $145,756 |
| FarxigaDapagliflozin Propanediol | 135 | $111,469 |
| KerendiaFinerenone | 73 | $64,792 |
| LokelmaSodium Zirconium Cyclosilicate | 44 | $53,669 |
| VeltassaPatiromer Calcium Sorbitex | 42 | $46,928 |
| RayaldeeCalcifediol | 31 | $41,231 |
| JardianceEmpagliflozin | 28 | $26,917 |
| LinzessLinaclotide | 12 | $10,946 |
| Bumetanide | 231 | $7,948 |
| Telmisartan | 237 | $6,900 |
| Sevelamer Carbonate | 28 | $5,634 |
| Febuxostat | 32 | $5,560 |
| Eplerenone | 12 | $3,089 |
| Chlorthalidone | 170 | $2,311 |
| Midodrine Hcl | 16 | $1,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $924 | $165,137179 claims |
| Fresenius USA Marketing, Inc.Velphoro | $532 | $145,75632 claims |
| BayerKerendia | $1,072 | $64,79273 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $233 | $41,23131 claims |
| Boehringer IngelheimJardiance | $136 | $26,91728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 229 nephrology providers in Tennessee.
Other nephrology in Memphis
- Omar HamzeMemphis$90K
- Omar DavisMemphis$70K
- Natarsha GrantMemphis$53K
- Marc StegmanMemphis$41K
- Robert CanadaMemphis$20K
- Minesh PathakMemphis$14K
- Miklos MolnarMemphis$12K
- Wael HusseinMemphis$10K
- Sanjeev MittalMemphis$9K
- Vasanthi BalaramanMemphis$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.